Cargando…

CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer

CRIPTO (CR-1, TDGF1) is a cell surface/secreted oncoprotein actively involved in development and cancer. Here, we report that high expression of CRIPTO correlates with poor survival in stratified risk groups of prostate cancer (PCa) patients. CRIPTO and its signaling partner glucose-regulated protei...

Descripción completa

Detalles Bibliográficos
Autores principales: Zoni, E, Chen, L, Karkampouna, S, Granchi, Z, Verhoef, E I, La Manna, F, Kelber, J, Pelger, R C M, Henry, M D, Snaar-Jagalska, E, van Leenders, G J L H, Beimers, L, Kloen, P, Gray, P C, van der Pluijm, G, Kruithof-de Julio, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562855/
https://www.ncbi.nlm.nih.gov/pubmed/28394345
http://dx.doi.org/10.1038/onc.2017.87
_version_ 1783258023523778560
author Zoni, E
Chen, L
Karkampouna, S
Granchi, Z
Verhoef, E I
La Manna, F
Kelber, J
Pelger, R C M
Henry, M D
Snaar-Jagalska, E
van Leenders, G J L H
Beimers, L
Kloen, P
Gray, P C
van der Pluijm, G
Kruithof-de Julio, M
author_facet Zoni, E
Chen, L
Karkampouna, S
Granchi, Z
Verhoef, E I
La Manna, F
Kelber, J
Pelger, R C M
Henry, M D
Snaar-Jagalska, E
van Leenders, G J L H
Beimers, L
Kloen, P
Gray, P C
van der Pluijm, G
Kruithof-de Julio, M
author_sort Zoni, E
collection PubMed
description CRIPTO (CR-1, TDGF1) is a cell surface/secreted oncoprotein actively involved in development and cancer. Here, we report that high expression of CRIPTO correlates with poor survival in stratified risk groups of prostate cancer (PCa) patients. CRIPTO and its signaling partner glucose-regulated protein 78 (GRP78) are highly expressed in PCa metastases and display higher levels in the metastatic ALDH(high) sub-population of PC-3M-Pro4Luc2 PCa cells compared with non-metastatic ALDH(low). Coculture of the osteotropic PC-3M-Pro4Luc2 PCa cells with differentiated primary human osteoblasts induced CRIPTO and GRP78 expression in cancer cells and increases the size of the ALDH(high) sub-population. Additionally, CRIPTO or GRP78 knockdown decreases proliferation, migration, clonogenicity and the size of the metastasis-initiating ALDH(high) sub-population. CRIPTO knockdown reduces the invasion of PC-3M-Pro4Luc2 cells in zebrafish and inhibits bone metastasis in a preclinical mouse model. These results highlight a functional role for CRIPTO and GRP78 in PCa metastasis and suggest that targeting CRIPTO/GRP78 signaling may have significant therapeutic potential.
format Online
Article
Text
id pubmed-5562855
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-55628552017-08-24 CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer Zoni, E Chen, L Karkampouna, S Granchi, Z Verhoef, E I La Manna, F Kelber, J Pelger, R C M Henry, M D Snaar-Jagalska, E van Leenders, G J L H Beimers, L Kloen, P Gray, P C van der Pluijm, G Kruithof-de Julio, M Oncogene Original Article CRIPTO (CR-1, TDGF1) is a cell surface/secreted oncoprotein actively involved in development and cancer. Here, we report that high expression of CRIPTO correlates with poor survival in stratified risk groups of prostate cancer (PCa) patients. CRIPTO and its signaling partner glucose-regulated protein 78 (GRP78) are highly expressed in PCa metastases and display higher levels in the metastatic ALDH(high) sub-population of PC-3M-Pro4Luc2 PCa cells compared with non-metastatic ALDH(low). Coculture of the osteotropic PC-3M-Pro4Luc2 PCa cells with differentiated primary human osteoblasts induced CRIPTO and GRP78 expression in cancer cells and increases the size of the ALDH(high) sub-population. Additionally, CRIPTO or GRP78 knockdown decreases proliferation, migration, clonogenicity and the size of the metastasis-initiating ALDH(high) sub-population. CRIPTO knockdown reduces the invasion of PC-3M-Pro4Luc2 cells in zebrafish and inhibits bone metastasis in a preclinical mouse model. These results highlight a functional role for CRIPTO and GRP78 in PCa metastasis and suggest that targeting CRIPTO/GRP78 signaling may have significant therapeutic potential. Nature Publishing Group 2017-08-17 2017-04-10 /pmc/articles/PMC5562855/ /pubmed/28394345 http://dx.doi.org/10.1038/onc.2017.87 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Original Article
Zoni, E
Chen, L
Karkampouna, S
Granchi, Z
Verhoef, E I
La Manna, F
Kelber, J
Pelger, R C M
Henry, M D
Snaar-Jagalska, E
van Leenders, G J L H
Beimers, L
Kloen, P
Gray, P C
van der Pluijm, G
Kruithof-de Julio, M
CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer
title CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer
title_full CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer
title_fullStr CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer
title_full_unstemmed CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer
title_short CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer
title_sort cripto and its signaling partner grp78 drive the metastatic phenotype in human osteotropic prostate cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562855/
https://www.ncbi.nlm.nih.gov/pubmed/28394345
http://dx.doi.org/10.1038/onc.2017.87
work_keys_str_mv AT zonie criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer
AT chenl criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer
AT karkampounas criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer
AT granchiz criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer
AT verhoefei criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer
AT lamannaf criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer
AT kelberj criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer
AT pelgerrcm criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer
AT henrymd criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer
AT snaarjagalskae criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer
AT vanleendersgjlh criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer
AT beimersl criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer
AT kloenp criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer
AT graypc criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer
AT vanderpluijmg criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer
AT kruithofdejuliom criptoanditssignalingpartnergrp78drivethemetastaticphenotypeinhumanosteotropicprostatecancer